ZFAND2A Inhibitors

ZFAND2A (AN1-Type Zinc Finger Protein 2A) Inhibitors target various pathways and processes such as the ubiquitin-proteasome system, autophagy, and cellular stress response, all of which are relevant to the biological context of ZFAND2A. Inhibitors like MG-132 [Z-Leu- Leu-Leu-CHO] and Bortezomib affect the ubiquitin-proteasome pathway, which is crucial for protein degradation and turnover, processes where ZFAND2A might have a role. Autophagy inhibitors like Chloroquine, Autophagy Inhibitor, 3-MA, Rapamycin, and Torin 1 are selected based on their ability to modulate the autophagy pathway, potentially influencing ZFAND2A's function.

Compounds such as SP600125 and SB 203580 target stress response pathways (JNK and p38 MAPK, respectively), which could intersect with ZFAND2A's role in cellular stress mechanisms. PI3K inhibitors LY 294002 and Wortmannin are included due to their broad impact on cellular signaling, including pathways that might be relevant to ZFAND2A. SBI-0206965 targets ATG5, an essential protein in autophagy. 17-AAG, an HSP90 inhibitor, is known to affect protein folding and stress response, potentially intersecting with ZFAND2A's functions. These inhibitors provide a spectrum of mechanisms that could indirectly modulate the activity of ZFAND2A by influencing pathways and processes in which this protein is potentially involved.